Summary of Epstein-Barr virus loads and tumor response in post-transplantation lymphoproliferative disease patients following rituximab therapy
| PTLD patients6-150 . | Number of EBV genomes per 106 PBMCs . | Tumor response . | |
|---|---|---|---|
| Pretreatment . | 5 weeks post-treatment . | ||
| P1 | 10 711 | 46 | Progressed |
| P2 | 15 073 | 222 | Progressed |
| P4 | 19 579 | 3 368 | Responded |
| P6 | 2 930 | 0 | —6-151 |
| P7 | 72 537 | 56-152 | Progressed |
| PTLD patients6-150 . | Number of EBV genomes per 106 PBMCs . | Tumor response . | |
|---|---|---|---|
| Pretreatment . | 5 weeks post-treatment . | ||
| P1 | 10 711 | 46 | Progressed |
| P2 | 15 073 | 222 | Progressed |
| P4 | 19 579 | 3 368 | Responded |
| P6 | 2 930 | 0 | —6-151 |
| P7 | 72 537 | 56-152 | Progressed |
PTLD indicates post-transplantation lymphoproliferative disease; PMBC, peripheral blood mononuclear cell.
All patients had CD20+, EBV+ B-cell lymphoma.
Patient P6 was inevaluable for tumor response because radiation therapy was used as primary treatment and the rituximab was used as consolidation.
This specimen was obtained 5 months post-treatment.